Lexicon Pharmaceuticals Q4 net loss narrows on lower R&D spend

Lexicon Pharmaceuticals

05/03/2026 12:07

Overview

Biopharmaceutical firm's Q4 revenue decreased significantly compared to last year

Net loss for Q4 narrowed to $15.5 mln from $33.8 mln last year

Company strengthened financial position with over $100 mln in additional cash

Outlook

Lexicon expects SONATA-HCM study enrollment to complete by mid-2026

Company plans NDA resubmission for ZYNQUISTA in 2026

Lexicon supports Viatris in regulatory filings for sotagliflozin in 2026

Result Drivers

EXPENSE REDUCTION - Decreased R&D and SG&A expenses contributed to a narrowed net loss for Q4 2025

Company press release: ID:nGNX5DRRX6

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Product Revenue
$1.06 mln
Q4 EPS
-$0.04
Q4 Net Income
-$15.53 mln
Q4 Basic EPS
-$0.04
Q4 Operating Expenses
$20.27 mln
Q4 Operating Income
-$14.78 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Lexicon Pharmaceuticals Inc is $3.05, about 87.1% above its March 4 closing price of $1.63

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)